Abstract
The enediyne antibiotics, the potent anticancer agents that contain diyne-ene functional groups, are appreciated for their novel molecular architecture, their remarkable biological activity and their fascinating mechanism of action. Their anticancer activity is apparently due to their ability to damage DNA through radical-mediated hydrogen abstraction. The enediyne antibiotics show markedly cytotoxicities against cancers in vitro and in vivo. Lidamycin is a member of the enediyne anticancer antibiotic family. This review examines lidamycin with particular emphasis on the discovery, the biological properties and its structure-activity relationships. In addition, the possible mechanisms of action of lidamycin are described. Recent progress, particularly in the areas of biosynthesis, and immunoconjugates are highlighted. Finally, the pharmacological applications of lidamycin in cancer therapy and its potential use as anticancer agents are also discussed.
Keywords: Lidamycin, Anticancer antibiotic, Enediyne, DNA damage, Cell cycle arrest, Apoptosis, Immunoconjugate, Cancer therapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Volume: 8 Issue: 2
Author(s): Rong-guang Shao and Yong-su Zhen
Affiliation:
Keywords: Lidamycin, Anticancer antibiotic, Enediyne, DNA damage, Cell cycle arrest, Apoptosis, Immunoconjugate, Cancer therapy
Abstract: The enediyne antibiotics, the potent anticancer agents that contain diyne-ene functional groups, are appreciated for their novel molecular architecture, their remarkable biological activity and their fascinating mechanism of action. Their anticancer activity is apparently due to their ability to damage DNA through radical-mediated hydrogen abstraction. The enediyne antibiotics show markedly cytotoxicities against cancers in vitro and in vivo. Lidamycin is a member of the enediyne anticancer antibiotic family. This review examines lidamycin with particular emphasis on the discovery, the biological properties and its structure-activity relationships. In addition, the possible mechanisms of action of lidamycin are described. Recent progress, particularly in the areas of biosynthesis, and immunoconjugates are highlighted. Finally, the pharmacological applications of lidamycin in cancer therapy and its potential use as anticancer agents are also discussed.
Export Options
About this article
Cite this article as:
Shao Rong-guang and Zhen Yong-su, Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/187152008783497055
DOI https://dx.doi.org/10.2174/187152008783497055 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Retinoblastoma Regulatory Pathway in Lung Cancer
Current Molecular Medicine CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design SUBJECT INDEX TO VOLUME 1
Current Pharmaceutical Biotechnology A Perspective on Stem Cells as Biological Systems that Produce Differentiated Osteoblasts and Odontoblasts
Current Stem Cell Research & Therapy Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Current Gene Therapy Strategies for Colorectal Cancer
Current Genomics Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor
Anti-Cancer Agents in Medicinal Chemistry Epigenetics in Ocular Diseases
Current Genomics Role of the Retinoblastoma Tumor Suppressor in the Maintenance of Genome Integrity
Current Molecular Medicine Alzheimers Disease and n-3 Polyunsaturated Fatty Acids: Beneficial Effects and Possible Molecular Pathways Involved
Current Signal Transduction Therapy